Laurus Labs Crecimiento futuro
Future controles de criterios 5/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Laurus Labs de 21.6% y 15.8% por año respectivamente. Se prevé que el BPA crezca en un 19.5% al año. Se espera que la rentabilidad financiera sea de 21.4% en 3 años.
Información clave
21.6%
Tasa de crecimiento de los beneficios
19.48%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 18.6% |
| Tasa de crecimiento de los ingresos | 15.8% |
| Rentabilidad financiera futura | 21.44% |
| Cobertura de analistas | Good |
| Última actualización | 08 Sep 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Artículo de análisis • Jul 27
Results: Laurus Labs Limited Beat Earnings Expectations And Analysts Now Have New Forecasts
Laurus Labs Limited ( NSE:LAURUSLABS ) just released its quarterly report and things are looking bullish. The company...Artículo de análisis • Jan 28
Results: Laurus Labs Limited Beat Earnings Expectations And Analysts Now Have New Forecasts
Laurus Labs Limited ( NSE:LAURUSLABS ) just released its quarterly report and things are looking bullish. It was...Recent updates
Actualización de narrativa • Sep 03
LAURUSLABS: Rich Pricing And Lower Future P/E Will Limit Upside
The analyst fair value estimate for Laurus Labs has been updated from ₹540.50 to ₹657.00 as analysts factor in revised assumptions on growth, margins, and valuation multiples informed by recent sector research commentary. Analyst Commentary Recent Street research on education companies offers a useful reference point for how bearish analysts may approach a stock like Laurus Labs when concerns build around valuation, execution, or growth expectations.
Actualización de narrativa • Aug 14
LAURUSLABS: Future Returns Will Depend On Resilient Margins Supporting Elevated P E Multiples
The Laurus Labs analyst price target has been updated from ₹1,044.00 to about ₹1,486.29. This change is supported by analyst assumptions that reflect higher revenue growth, stronger profit margins and a modestly higher future P/E, while keeping the discount rate broadly similar.
Actualización de narrativa • Jul 31
LAURUSLABS: Higher Margin Outlook And Upcoming Results Dates Will Shape Future Appeal
Analysts have lifted the Laurus Labs fair value estimate from ₹1,370 to ₹1,980, reflecting updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple. Analyst Commentary For Laurus Labs, the latest fair value revision sits against a broader backdrop of how bullish analysts are thinking about education and healthcare related names, including companies with similar growth and cash generation profiles.Artículo de análisis • Jul 27
Results: Laurus Labs Limited Beat Earnings Expectations And Analysts Now Have New Forecasts
Laurus Labs Limited ( NSE:LAURUSLABS ) just released its quarterly report and things are looking bullish. The company...Actualización de narrativa • Jul 17
LAURUSLABS: Lower Future P/E Assumptions Will Continue To Restrain Margin Upside
Analysts now see Laurus Labs' fair value at about ₹540.50, down from roughly ₹606.49. This reflects updated assumptions on future P/E levels as well as refreshed revenue growth and margin estimates.Actualización de narrativa • Jul 02
LAURUSLABS: Currency And Execution Risks Will Continue To Restrain Margin Upside
Analysts have revised their fair value estimate for Laurus Labs to ₹606.49 from ₹543.09, citing updated assumptions around revenue growth, profit margins, and a slightly higher future P/E multiple. What’s in the News for Laurus Labs Laurus Labs has scheduled a board meeting on April 30, 2026, at 14:00 IST to consider audited financial results for the quarter and year ended March 31, 2026, along with several corporate actions.Actualización de narrativa • Jun 18
LAURUSLABS: Dividend Moves And Governance Changes Will Shape Future Stock Appeal
Analysts have raised their fair value estimate for Laurus Labs to ₹1,370 from ₹1,270, reflecting updated assumptions around slightly adjusted growth, lower profit margins and a higher future P/E multiple in their latest models. Analyst Commentary Bullish analysts looking at Laurus Labs are focusing on how updated assumptions flow through to valuation, execution expectations and potential growth drivers.Actualización de narrativa • Jun 03
LAURUSLABS: Future Returns Will Depend On Sustained Confidence In Higher P E Multiples
Analysts have lifted their fair value estimate for Laurus Labs stock to ₹1,044 from ₹913, reflecting updated assumptions around modestly higher revenue growth, improved profit margins and revised future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts see the higher fair value estimate as consistent with updated assumptions for Laurus Labs, where modestly higher revenue expectations support a richer long term P/E framework.Actualización de narrativa • Apr 30
LAURUSLABS: Upcoming Dividend Decision And Stable Assumptions Will Support Future Upside
Analysts have kept the Laurus Labs fair value estimate unchanged at ₹1,270, with small tweaks to revenue growth, profit margin and P/E assumptions. These reflect updated models rather than a shift in overall conviction.Actualización de narrativa • Apr 15
LAURUSLABS: Stronger Fundamentals And Upcoming Board Decisions Will Support Upside
Analysts have slightly reduced the Laurus Labs fair value estimate to ₹1,270 from ₹1,280 after updating assumptions on revenue growth, margins, and future P/E, while keeping the overall risk profile unchanged. Analyst Commentary Recent Street research on a different company, Laureate Education, still gives you a sense of how bullish analysts may think when they see improving fundamentals, supportive macro factors, or cleaner execution.Actualización de narrativa • Apr 01
LAURUSLABS: Currency And Execution Uncertainties Will Likely Cap Margin Upside
Analysts have made a small upward tweak to the Laurus Labs fair value estimate, with the price target moving from ₹540.28 to ₹543.09. This reflects updated assumptions on revenue growth and profitability.Actualización de narrativa • Mar 18
LAURUSLABS: Higher Margin Assumptions Will Likely Struggle Against Execution Risks
Narrative Update on Laurus Labs The updated analyst price target for Laurus Labs moves from about ₹330 to roughly ₹540. Analysts point to revised assumptions for margins and future P/E, along with broadly steady growth expectations, as key drivers of the change.Actualización de narrativa • Mar 04
LAURUSLABS: Steady Fair Value And Solid Fundamentals Will Support Upside
Analysts have kept their price target for Laurus Labs steady at ₹1,280, reflecting small adjustments to assumptions on discount rate, revenue growth, profit margin and future P/E. These changes are consistent with recent Street research, where targets shifted within a relatively tight range and analysts cited solid fundamentals alongside mixed near term signals.Actualización de narrativa • Feb 18
LAURUSLABS: Future Returns Will Rely On Confidence In Elevated P E Assumptions
Narrative Update: Laurus Labs Analyst Price Target Analysts have maintained their Laurus Labs price target at ₹913.47, citing largely unchanged assumptions around revenue, profit margins, discount rate, and forward P/E as the basis for keeping fair value steady. Analyst Commentary Analysts covering Laurus Labs are using a similar playbook to recent work on other education and healthcare names, where price targets are adjusted mainly on valuation inputs rather than big changes in growth assumptions.Actualización de narrativa • Feb 03
LAURUSLABS: Future Returns Will Depend On Confidence In Rich P E Assumptions
Analysts have lifted their fair value estimate for Laurus Labs from ₹863.13 to ₹913.47, citing slightly higher assumptions for revenue growth, profit margins and future P/E multiples, consistent with recent upward target revisions seen in related Street research. Analyst Commentary Bullish analysts point to the higher fair value estimate of ₹913.47 as support for a more constructive view on Laurus Labs, even though inputs are only slightly adjusted.Artículo de análisis • Jan 28
Results: Laurus Labs Limited Beat Earnings Expectations And Analysts Now Have New Forecasts
Laurus Labs Limited ( NSE:LAURUSLABS ) just released its quarterly report and things are looking bullish. It was...Artículo de análisis • Jan 25
Laurus Labs Limited's (NSE:LAURUSLABS) Popularity With Investors Is Under Threat From Overpricing
With a price-to-earnings (or "P/E") ratio of 65.1x Laurus Labs Limited ( NSE:LAURUSLABS ) may be sending very bearish...Actualización de narrativa • Jan 20
LAURUSLABS: Future Returns Will Depend On Rich P E Assumptions Holding
Analysts have lifted their price target for Laurus Labs to ₹863 from about ₹822, reflecting updated assumptions on fair value, profit margins, and future P/E multiples. Analyst Commentary Bullish Takeaways Bullish analysts view the higher price target as a sign that current assumptions on Laurus Labs' fair value leave room for upside if the company executes consistently on profitability.Actualización de narrativa • Jan 06
LAURUSLABS: Interim Dividend And Higher P E Multiple Will Support Upside
Analysts have raised their price target on Laurus Labs from ₹1,025 to ₹1,280, citing updated assumptions for revenue growth, profit margins, and a higher future P/E multiple. What's in the News The Board of Directors approved an interim dividend of ₹0.80 per equity share of face value ₹2 for the 2025-26 financial year at the meeting held on October 23, 2025 (company filing).Actualización de narrativa • Dec 21
LAURUSLABS: Interim Dividend May Not Offset Softer Margins Ahead
Analysts have moderately raised their price target on Laurus Labs from ₹303.09 to ₹330.21, citing a slightly higher justified valuation multiple that more than offsets their marginally softer assumptions on revenue growth and profit margins. What's in the News The Board approved an interim dividend of INR 0.80 per equity share (40 percent of the face value of INR 2) for FY 2025-26, signaling confidence in cash flows and shareholder returns (company filing).Actualización de narrativa • Dec 07
LAURUSLABS: Future Returns Will Likely Hinge On Managing Execution Risks
Analysts have modestly increased their price target for Laurus Labs while maintaining fair value at ₹821.93, citing expectations of sustained earnings growth supported by a solid balance sheet, margin expansion, and revenue momentum from new market opportunities. Analyst Commentary Street research on comparable growth stories in the education and healthcare sectors highlights themes that are directly relevant for Laurus Labs, particularly around how markets price in multi year earnings expansion, balance sheet strength, and scalability in new markets.Actualización de narrativa • Nov 23
LAURUSLABS: Future Revenue Upside May Be Limited By Execution Risks
Analysts have raised their price target for Laurus Labs slightly, from ₹815.86 to ₹821.93. They cite expectations of stronger revenue growth supported by a robust balance sheet and expanding opportunities in new markets.Actualización de narrativa • Nov 04
LAURUSLABS: Margin Pressures From Rising Input Costs Will Weigh On Earnings
Analysts have raised their fair value price target for Laurus Labs from ₹724.14 to ₹815.86. They cite increased profitability outlook and sustained margin growth as key drivers for the revision.Artículo de análisis • Oct 30
Laurus Labs' (NSE:LAURUSLABS) Dividend Will Be ₹0.80
Laurus Labs Limited ( NSE:LAURUSLABS ) will pay a dividend of ₹0.80 on the 22nd of November. Even though the dividend...Actualización de narrativa • Oct 21
Analysts Cite Growth Momentum and Strong Balance Sheet in Raising Laurus Labs Valuation Estimates
Analysts have raised their fair value estimate for Laurus Labs from ₹694.85 to ₹724.14. They cite continued revenue growth momentum and a strong balance sheet as key drivers for this upward revision.Artículo de análisis • Oct 19
With Laurus Labs Limited (NSE:LAURUSLABS) It Looks Like You'll Get What You Pay For
Laurus Labs Limited's ( NSE:LAURUSLABS ) price-to-sales (or "P/S") ratio of 8.2x may look like a poor investment...
Nueva narrativa • Jan 26
CDMO Expansion May Impact Near-Term Margins But Pave Way For Future Revenue Streams
Heavy investment in CDMO and microbial precision initiatives may lead to revenue delays and short-term margin compression due to underutilized assets.Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 3/31/2029 | 114,362 | 21,391 | 8,543 | N/A | 8 |
| 3/31/2028 | 95,489 | 15,719 | 4,449 | N/A | 15 |
| 3/31/2027 | 83,396 | 13,714 | -3,973 | N/A | 12 |
| 6/30/2026 | 72,696 | 10,934 | N/A | N/A | N/A |
| 3/31/2026 | 68,129 | 8,888 | 5,536 | 16,235 | N/A |
| 12/31/2025 | 67,216 | 8,433 | N/A | N/A | N/A |
| 9/30/2025 | 63,584 | 6,840 | 7,696 | 16,375 | N/A |
| 6/30/2025 | 59,286 | 5,088 | N/A | N/A | N/A |
| 3/31/2025 | 55,540 | 3,583 | -393 | 6,017 | N/A |
| 12/31/2024 | 52,733 | 2,003 | N/A | N/A | N/A |
| 9/30/2024 | 50,532 | 1,311 | -3,277 | 2,489 | N/A |
| 6/30/2024 | 50,540 | 1,482 | N/A | N/A | N/A |
| 3/31/2024 | 50,408 | 1,606 | -126 | 6,657 | N/A |
| 12/31/2023 | 49,821 | 1,879 | N/A | N/A | N/A |
| 9/30/2023 | 53,320 | 3,678 | 2,870 | 12,248 | N/A |
| 6/30/2023 | 56,834 | 5,637 | N/A | N/A | N/A |
| 3/31/2023 | 60,406 | 7,901 | 37 | 9,939 | N/A |
| 12/31/2022 | 60,845 | 9,176 | N/A | N/A | N/A |
| 9/30/2022 | 55,684 | 8,683 | 13 | 8,393 | N/A |
| 6/30/2022 | 51,960 | 8,374 | N/A | N/A | N/A |
| 3/31/2022 | 49,356 | 8,275 | 343 | 9,111 | N/A |
| 12/31/2021 | 49,227 | 8,937 | N/A | N/A | N/A |
| 9/30/2021 | 51,823 | 10,128 | -1,705 | 7,112 | N/A |
| 6/30/2021 | 51,177 | 10,532 | N/A | N/A | N/A |
| 3/31/2021 | 48,135 | 9,836 | 442 | 7,330 | N/A |
| 12/31/2020 | 42,407 | 7,971 | N/A | N/A | N/A |
| 9/30/2020 | 36,819 | 5,977 | 1,548 | 5,427 | N/A |
| 6/30/2020 | 32,555 | 4,120 | N/A | N/A | N/A |
| 3/31/2020 | 28,317 | 2,553 | N/A | 3,474 | N/A |
| 12/31/2019 | 26,277 | 1,883 | N/A | N/A | N/A |
| 9/30/2019 | 24,276 | 1,326 | N/A | 3,538 | N/A |
| 6/30/2019 | 23,035 | 923 | N/A | N/A | N/A |
| 3/31/2019 | 22,919 | 938 | N/A | 2,977 | N/A |
| 12/31/2018 | 22,170 | 957 | N/A | N/A | N/A |
| 9/30/2018 | 21,665 | 1,127 | N/A | N/A | N/A |
| 6/30/2018 | 21,168 | 1,453 | N/A | N/A | N/A |
| 3/31/2018 | 20,562 | 1,676 | N/A | 3,425 | N/A |
| 12/31/2017 | 19,687 | 1,917 | N/A | N/A | N/A |
| 9/30/2017 | 19,954 | 2,019 | N/A | N/A | N/A |
| 6/30/2017 | 19,733 | 2,014 | N/A | N/A | N/A |
| 3/31/2017 | 19,046 | 1,881 | N/A | 3,320 | N/A |
| 3/31/2016 | 17,776 | 1,337 | N/A | 1,820 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (21.6% al año) de LAURUSLABS es superior a la tasa de ahorro (6.9%).
Beneficios vs. Mercado: Se prevé que los beneficios (21.6% al año) de LAURUSLABS crezcan más rápidamente que el mercado Indian (16.8% al año).
Beneficios de alto crecimiento: Se espera que los beneficios de LAURUSLABS crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (15.8% al año) de LAURUSLABS crezcan más rápidamente que los del mercado Indian (11.3% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 15.8% al año) de LAURUSLABS crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de LAURUSLABS sea alta dentro de 3 años (21.4%)
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/14 08:52 |
| Precio de las acciones al final del día | 2026/09/11 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2026/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Laurus Labs Limited está cubierta por 26 analistas. 15 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Ashwin Mehta | Ambit Capital |
| null null | Antique Stockbroking Ltd. |